Dirk Rades1, Liesa Dziggel2, Tobias Bartscht3, Jan Gliemroth4. 1. Department of Radiation Oncology, University of Lübeck, Lübeck, Germany rades.dirk@gmx.net. 2. Department of Radiation Oncology, University of Lübeck, Lübeck, Germany. 3. Department of Medical Oncology and Hematology, University of Lübeck, Lübeck, Germany. 4. Department of Neurosurgery, University of Lübeck, Lübeck, Germany.
Abstract
AIM: To identify survival predictors and develop a survival score for patients with brain metastases from esophageal cancer. PATIENTS AND METHODS: In 16 patients, seven factors were analyzed including age, gender, Karnofsky performance score (KPS), time from diagnosis of esophageal cancer to irradiation, number of brain metastases, histology, and presence of extracerebral metastases. RESULTS: Improved survival was significantly associated with KPS≥80 (p<0.001), the presence of one brain metastasis (p=0.007), and no extra-cerebral metastases (p=0.002). These factors were included in the final score. Factor scores were calculated by dividing 6-month survival rates by 10. Total survival scores represented the sums of factor scores and were 2, 7, 10, 19 or 24 points. Six-month survival rates by score were 0%, 0%, 0%, 67% and 100%, respectively. Two groups were formed, those of patients with 2-10 points and those with 19-24 points; 6-month survival was 0% and 88%, respectively (p<0.001). CONCLUSION: This new score facilitates the selection of individual therapies for patients with brain metastases from esophageal cancer. Copyright
AIM: To identify survival predictors and develop a survival score for patients with brain metastases from esophageal cancer. PATIENTS AND METHODS: In 16 patients, seven factors were analyzed including age, gender, Karnofsky performance score (KPS), time from diagnosis of esophageal cancer to irradiation, number of brain metastases, histology, and presence of extracerebral metastases. RESULTS: Improved survival was significantly associated with KPS≥80 (p<0.001), the presence of one brain metastasis (p=0.007), and no extra-cerebral metastases (p=0.002). These factors were included in the final score. Factor scores were calculated by dividing 6-month survival rates by 10. Total survival scores represented the sums of factor scores and were 2, 7, 10, 19 or 24 points. Six-month survival rates by score were 0%, 0%, 0%, 67% and 100%, respectively. Two groups were formed, those of patients with 2-10 points and those with 19-24 points; 6-month survival was 0% and 88%, respectively (p<0.001). CONCLUSION: This new score facilitates the selection of individual therapies for patients with brain metastases from esophageal cancer. Copyright
Authors: Nishi Kothari; Eric Mellon; Sarah E Hoffe; Jessica Frakes; Ravi Shridhar; Jose Pimiento; Ken Meredith; Nam D Tran; Nadia Saeed; Khaldoun Almhanna Journal: J Gastrointest Oncol Date: 2016-08
Authors: Linlin Xiao; Yvonne M Mowery; Brian G Czito; Yajing Wu; Guangbin Gao; Chang Zhai; Jianing Wang; Jun Wang Journal: Front Oncol Date: 2021-04-29 Impact factor: 6.244